One provision of the Lower Health Care Costs Act that has garnered significantly less attention from the broader healthcare community has raised concerns among many biologics stakeholders.
USP in the News
Center for Biosimilars
Little-Known Provision of Senate Healthcare Bill Has Some Biosimilar Stakeholders Worried
ScienceDirect
Commentary on the Benefits of US Pharmacopeial Standards: A Generic Pharmaceutical Industry Survey
Unpublished data suggest that pharmacopeial quality standards, while not associated with increasing the likelihood of a first generic entrant in the market, are associated with increasing the overall number of generic entrants.
News Releases & Announcements
January 06, 2020
Quality Matters Blog
What does the future of health IT look like?
The digitization of healthcare must be effectively structured to optimize care, therapies, access, and outcomes.
USP volunteers help shape the future of drug manufacturing
Consistent quality. Greater access. They’re what patients deserve and what USP strives to ensure across the globe through the development of public quality standards.
A new generation of tools and standards for biologic medicine quality
USP standards have evolved to accommodate medicines of all types. The biosimilar paradigm may ultimately resemble that of generic drugs.
Stay Connected…
Sign up for the latest USP News Releases!